Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?

(2016) Roger P. A’Hern   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

(2016) Ludovic Trinquart et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply

(2016) Arlene Chan et al.   LANCET ONCOLOGY

Neratinib after trastuzumab in patients with HER2-positive breast cancer

(2016) Takahiro Hasegawa et al.   LANCET ONCOLOGY

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2016) Arlene Chan et al.   LANCET ONCOLOGY

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

(2016) Julien Péron et al.   Oncotarget

The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials

(2016) Julien Péron et al.   JAMA Oncology

Describing Differences in Survival Curves

(2016) Rick Chappell et al.   JAMA Oncology

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

(2015) J Péron et al.   BRITISH JOURNAL OF CANCER

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Individualizing treatment choices using quantitative methods

(2014) Stuart J. Pocock et al.   AMERICAN HEART JOURNAL

Evidence-Based Risk Communication

(2014) Daniella A. Zipkin et al.   ANNALS OF INTERNAL MEDICINE

Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors

(2014) A. F. Sobrero et al.   CLINICAL CANCER RESEARCH

Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer

(2014) Michael Coory et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect

(2014) Patrick Royston et al.   Trials

Bias and Sensitivity Analysis When Estimating Treatment Effects from the Cox Model with Omitted Covariates

(2013) Nan Xuan Lin et al.   BIOMETRICS

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods

(2012) B. Seruga et al.   ANNALS OF ONCOLOGY

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Hazard ratios in cancer clinical trials—a primer

(2012) Krastan B. Blagoev et al.   Nature Reviews Clinical Oncology

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

(2011) S. J. Pocock et al.   EUROPEAN HEART JOURNAL

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials

(2010) Everardo D. Saad et al.   JOURNAL OF CLINICAL ONCOLOGY

How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials

(2010) Belinda E. Kiely et al.   JOURNAL OF CLINICAL ONCOLOGY

When Are "Positive" Clinical Trials in Oncology Truly Positive?

(2010) A. Ocana et al.   JNCI-Journal of the National Cancer Institute

Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer: A Status Report for 2009 from the ClinicalTrials.gov Website

(2010) Janakiraman Subramanian et al.   Journal of Thoracic Oncology

Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

(2010) Marc Buyse   STATISTICS IN MEDICINE

The Hazards of Hazard Ratios

(2009) Miguel A. Hernán   EPIDEMIOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reformulating the hazard ratio to enhance communication with clinical investigators

(2008) Marc Buyse   Clinical Trials

Reformulating the hazard ratio to enhance communication with clinical investigators

(2008) Barry K Moser et al.   Clinical Trials

Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception

(2008) Leonard B. Saltz   JOURNAL OF CLINICAL ONCOLOGY

Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots

(2008) P. Royston et al.   JNCI-Journal of the National Cancer Institute